The massive EPS miss reflects early-stage biotech R&D spending with no revenue, typical for pre-commercial companies. The BH-501284 preclinical data is a positive pipeline catalyst but does not offset the earnings miss. Watch for IND filing in Q1 2027 and any clinical data updates for BH-30643 or BH-30236.
Price Chart
Executive Summary
BlossomHill Therapeutics reported Q2 2026 EPS of -$8.75, a 874% miss vs consensus of -$0.90, with zero revenue. The company also presented preclinical data for its pan-KRAS inhibitor BH-501284 at an AACR conference, showing prolonged target engagement and durable antitumor activity across multiple KRAS-mutant models, supporting an IND submission in Q1 2027.
Key Financial Metrics
Key Facts
- Q2 2026 EPS of -$8.75 vs consensus -$0.90 (-874% miss)
- Zero revenue reported for the quarter
- Preclinical data for BH-501284 presented at AACR Pancreatic Cancer Conference
- BH-501284 showed target residence time >54 hours in SPR study
- IND submission for BH-501284 planned for Q1 2027
- Lead program BH-30643 is an EGFR inhibitor in clinical development for NSCLC
- BH-30236 is a CLK inhibitor in clinical trials for R/R AML and HR-MDS
Financial Impact
EPS miss of -$7.85 per share vs consensus; no revenue generated
Risk Factors
- Preclinical data may not translate to clinical success
- No approved products or revenue; dependent on financing
- Competition from other KRAS-targeted therapies
- Regulatory and clinical development risks for all pipeline candidates
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3369749 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 28, 2026 29d ago | Press Release | $21.34 $16.39 | ▲ +23.20% | ▲ +23.16% | $16.50 (+22.68%) |
Sep 18, 2026 5w ago | 8-K | $25.74 $13.94 | ▲ +45.84% | ▲ +46.05% | $16.50 (+35.90%) |
Sep 18, 2026 5w ago | Press Release | $25.74 $13.94 | ▼ −45.84% | ▼ −46.05% | $16.50 (−35.90%) |
Sep 15, 2026 6w ago | 8-K | $22.17 $15.48 | ▼ −30.18% | ▼ −33.15% | $16.50 (−25.58%) |
Aug 12, 2026 10w ago | Insider Cluster | $16.35 $20.86 | ▲ +27.58% | ▲ +29.33% | $16.50 (+0.92%) |
Aug 10, 2026 11w ago | Insider Cluster | $16.52 $22.00 | ▲ +33.17% | ▲ +34.23% | $16.50 (−0.12%) |
Aug 10, 2026 11w ago | 8-K | $16.52 $22.00 | ▲ +33.17% | ▲ +34.23% | $16.50 (−0.12%) |
Aug 7, 2026 11w ago | 424B4 | $15.99 $22.93 | ▲ +43.40% | ▲ +44.32% | $16.50 (+3.19%) |
Aug 7, 2026 11w ago | EFFECT | $16.00 $22.01 | ▲ +37.56% | ▲ +37.96% | $16.50 (+3.13%) |
Aug 6, 2026 11w ago | 3 | $16.00 $22.01 | ▲ +37.56% | ▲ +37.96% | $16.50 (+3.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers